Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients

18 Jun 2021

Abstract excerpt

With the introduction of novel therapeutic agents, survival in Multiple Myeloma (MM) has increased in recent years. However, drug-resistant clones inevitably arise and lead to disease progression and death. The current International Myeloma Working Group response criteria are broad and make it difficult to clearly designate resistant and responsive patients thereby hampering proteo-genomic analysis for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34145309
DOI: 10.1038/s41598-021-90149-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patientsPMID 34145309Read ↗

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.Semantic proximity Read ↗

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaSemantic proximity Read ↗

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistanceSemantic proximity Read ↗

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.Semantic proximity Read ↗

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaSemantic proximity Read ↗

Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myelomaSemantic proximity Read ↗

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.Semantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted TreatmentSemantic proximity Read ↗

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Semantic proximity Read ↗

Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myelomaSemantic proximity Read ↗

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.